U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297134) titled 'PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer' on Dec. 09.
Brief Summary: This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy c...